Healthcare entity
All 1 tracked stories fall under one category: market-trends. Skye Bioscience is most often covered alongside Evolv Technologies, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 4.1 across the same-window beat baseline.
Last mentioned: Mar 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: market-trends. Skye Bioscience is most often covered alongside Evolv Technologies, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 4.1 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6 for that window. We currently track 1 Healthcare story that mention Skye Bioscience, all published on March 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Skye Bioscience. Shared-story counts are live from our verified record — not editorial picks.
Evolv Technologies and Skye Bioscience are set to report Q4 2025 results, highlighting two critical growth vectors in the healthcare ecosystem: AI-driven physical security and metabolic clinical innovation. While Evolv faces a pivotal moment in hospital infrastructure adoption, Skye’s update will be scrutinized for progress in the competitive obesity therapeutics market.
Source: Seeking Alpha · Seeking Alpha
Skye Bioscience is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
